Tag Archives: OTC

Business, Finance, Occupation & Industry

Technip Awarded Contract for the P-76 FPSO in Brazil

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Technip Awarded Contract for the P-76 FPSO in Brazil

PARIS–(BUSINESS WIRE)– Regulatory News:

Technip (Paris:TEC) (ISIN:FR0000131708), leader of a 50/50 consortium with Techint, was awarded by PNBV(1) a substantial(2) contract for the topside construction and integration, the commissioning and start up assistance of the P-76 floating production storage and offloading (FPSO) unit. Located in the Santos Basin pre-salt area offshore Rio de Janeiro, Brazil, this unit will produce 180,000 barrels of oil and 7 million cubic meters per day of gas.

Technip’s operating center in Rio de Janeiro will perform the project management, engineering and procurement. The 24,000-ton modules fabrication, integration and commissioning will be performed in Techint’s yard, in the South of Brazil. The project is scheduled to be completed by mid-2017.

José Jorge Araújo, Technip’s Senior Vice President Onshore Latin America and Offshore Brazil, declared: “We are delighted to have the opportunity to keep working with Petrobras. This contract strengthens furthermore our presence in the burgeoning Brazilian offshore pre-salt market, where our leading-edge position enables us to meet its high standards and requirements. We fully expect that our partnership with Techint will be a key to the success of the P-76 FPSO. Moreover, this project will contribute to the local economy as it will require approximately 70% of Brazilian local content.“

____

(1) PNBV is an integral subsidiary of Petrobras S.A.

(2) For Technip, a “substantial” offshore contract is ranging from €250 to €500 million.

°

° °

Technip is a world leader in project management, engineering and construction for the energy industry.

From the deepest Subsea oil & gas developments to the largest and most complex Offshore and Onshore infrastructures, our 36,500 people are constantly offering the best solutions and most innovative technologies to meet the world’s energy challenges.

Present in 48 countries, Technip has state-of-the-art industrial assets on all continents and operates a fleet of specialized vessels for pipeline installation and subsea construction.

Technip shares are listed on the NYSE Euronext Paris exchange and the USA over-the-counter (OTC) market as an American Depositary Receipt (ADR: TKPPY).

Technip

From: http://www.dailyfinance.com/2013/04/17/technip-awarded-contract-for-the-p-76-fpso-in-braz/

Business, Finance, Occupation & Industry

United Mine Services, Inc. Secures Contract for Mine Services with ABM Mining Corporation

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

United Mine Services, Inc. Secures Contract for Mine Services with ABM Mining Corporation

VANCOUVER, British Columbia–(BUSINESS WIRE)– United Silver Corp. (“United Silver Corp.”, the “Company”, or “USC“: TSX; USC: OTC; USCZF: Frankfurt: UM8) is pleased to announce that its subsidiary, United Mine Services, Inc. (UMS) has secured a contract to provide ongoing mine services for ABM Mining Corporation, a subsidiary of ASX and AIM listed Black Mountain Resources Limited, at their New Departure Mine near Dillon, Montana. Services will include rehabilitation of existing workings as well as new tunneling and related support services. Crews have mobilized to the site and work on the project has started.

Greg Stewart, CEO of United Mine Services, Inc. says ” UMS is very pleased to provide mine services to ABM. We look forward to building a long standing working relationship going forward.”

ABOUT UNITED SILVER CORP.

USC is a vertically integrated Canadian mining company with operations in Idaho, USA. It has an 80% interest in the Crescent Silver Mine project in the Silver Valley‘s prolific Silver Belt – directly between two of the district’s historically largest silver producing properties, the Sunshine and Bunker Hill mines. USC also offers a full suite of mining services including contract mining and providing a complete fabrication shop and service for building and repairing mining equipment to silver miners in the district. USC‘s common shares trade on the Toronto Stock Exchange under the symbol “USC“. For more information about USC, please visit: www.unitedsilvercorp.com

ON BEHALF OF UNITED SILVER CORP.


“Graham Clark”


Chairman and CEO

Investor Relations
Tel. (855) 238-0202

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

United Silver Corp.
Investor Relations
Graham Clark, 855-238-0202
Chairman and CEO

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:

From: http://www.dailyfinance.com/2013/04/11/united-mine-services-inc-secures-contract-for-mine/

Business, Finance, Occupation & Industry

IGI Laboratories to Hold Conference Call for 1st Quarter 2013 Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

IGI Laboratories to Hold Conference Call for 1st Quarter 2013 Results

BUENA, N.J.–(BUSINESS WIRE)– IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:30 pm ET on Thursday, April 25, 2013 to discuss 1st quarter 2013 results.

The Company invites you to listen to the call by dialing 1-866-515-2913. International participants should call 1-617-399-5127. The passcode for the conference call is 36836952.

This call is being webcast by Thomson and can be accessed at IGI‘s website at www.igilabs.com.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents (www.streetevents.com), a password-protected event management site.

About IGI Laboratories, Inc.

IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

IGI Laboratories, Inc.
Jenniffer Collins, 856-697-1441
www.igilabs.com

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:

The article IGI Laboratories to Hold Conference Call for 1st Quarter 2013 Results originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);

From: http://www.dailyfinance.com/2013/04/11/igi-laboratories-to-hold-conference-call-for-1st-q/

Business, Finance, Occupation & Industry

Greyson International Provides Update on Prospective Biomedical Subsidiary

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Greyson International Provides Update on Prospective Biomedical Subsidiary

COCONUT CREEK, Fla.–(BUSINESS WIRE)– Greyson International Inc. (OTC Pink: GYSN), developer of an innovative, patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that Greyson is forming a subsidiary that will have a business plan which will target the multi-billion dollar pharmaceutical industry.

“Greyson’s management team has been diligently working to launch our new Greyson Biomedical subsidiary and commercialize Trilexon® Delivery System in potentially enormous medical end markets,” said Greyson International Inc. CEO Harvey Tauman. “After demonstrating efficacy in topical applications in OTC products, our goal is to license our patented technology to companies interested in improving efficacy of their existing products or creating altogether new products.”

Greyson International‘s patented Trilexon® technology (U.S. Patent 8,268,335) combines a cationic emulsifying agent, oil soluble liquid polymer and naturally occurring lactate buffer system to dramatically improve the topical delivery of active ingredients. Unlike normal delivery agents, the patented formulation effectively delivers active ingredients to the skin at a more desirable pH level to enhance delivery/efficacy.

“We believe there is a lot of potential for Trilexon® Delivery System within the biomedical industry,” added CEO Harvey Tauman. “With more durable and stable delivery of active ingredients, we see potential in prescription products that promote healing, restore damaged cells, and relieve topical pain, as well as topical OTC products like pain relievers, eczema treatment, anti-etch creams, burn relief products, or sunscreens etc. Our team is working diligently to prove these claims and launching the new subsidiary in the near future in order to generate significant long-term value for our shareholders.”

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system that’s taking the multi-billion dollar cosmetics and OTC pharmaceuticals industries by storm. Based on this technology, the company’s patented Trilexon® foundation creates a fine surface that is insoluble in water, keeping it in place even after sweating or contact with water. Ingredients are released continuously over an extended period of time, ensuring that the skin receives treatment at a constant steady pace to give it a healthy and youthful look. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International. The company also holds an investment in Blake Oil and Gas Limited (“Blake”), a privately owned, Guernsey registered, Oil and Gas Company. For more information,

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Sapient Global Markets Facilitates Compliance Reporting with DTCC's Swap Data Repository

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Sapient Global Markets Facilitates Compliance Reporting with DTCC’s Swap Data Repository

Sapient’s Compliance Management and Reporting System Drives Efficiencies across all Asset Classes for Required SDR Reporting

BOSTON–(BUSINESS WIRE)– Sapient Global Markets has today announced its Compliance Management and Reporting System (CMRS) will be offered for customers connecting to The Depository Trust & Clearing Corporation (DTCC) Swap Data Repository (SDR) reporting. CMRS provides firms with a complete solution for more efficiently and effectively meeting regulatory reporting commitments.

Regulations, such as the Dodd-Frank Act, European Market Infrastructure Regulation (EMIR) and the Regulation on Energy Market Integrity and Transparency (REMIT), are increasing reporting requirements for firms in the capital and commodity markets. Sapient’s CMRS allows firms to collate vast amounts of data from disparate systems, translate it into the destination message format, deliver it directly to regulators and receive acknowledgement messages back from DTCC. Additionally, it provides a single view of compliance regardless of operating model and required reporting venue.

“DTCC is focused on delivering to our clients world-wide effective solutions that bring greater cost efficiency, transparency and risk mitigation to the OTC derivatives market. Our global trade reporting platform is designed with an open architecture which allows a wide universe of market participants to gain seamless access to our services which help them meet their regulatory reporting requirements around the world,” said Chris Childs, managing director, Deriv/SERV. “Working with complementary solution providers such as Sapient Global Markets and connecting with CMRS is a prime example of how we look to accomplish just that and jointly help our mutual clients face the challenges of an evolving regulatory landscape.”

Designed for firms doing business across borders, CMRS connects to all major trading and risk management systems that process high volumes of swaps and other OTC products. It is SDR agnostic and is the only system to date that collects and normalizes data from multiple sources before transforming it into formats accepted by regulatory reporting destinations. It is this end-to-end capability that ensures firms concerned with swap data reporting have a single view of compliance regardless of operating model and required reporting venue.

“As regulatory reporting deadlines approach, firms must achieve a single view of their compliance status and a streamlined method of translating data from multiple sources into the format required by regulators,” said Arun Karur, vice president, Sapient Global Markets. “With connection to the DTCC, we are offering our …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Technip : General Shareholders' Meeting on April 25, 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Technip : General Shareholders’ Meeting on April 25, 2013

Availability of the Shareholders’ Meeting documents

PARIS–(BUSINESS WIRE)– Regulatory News:

Technip (Paris:TEC) (ISIN:FR0000131708) (ADR:TKPPY):

Technips’ Shareholders are invited to participate to Technip’s Shareholders’ Meeting which will be held on Thursday, April 25, 2013, at 3:00 p.m. at Auditorium Paris Centre Marceau, 12 avenue Marceau – 75008 Paris (France).

The Notice including the Agenda and the draft resolutions was published in the BALO (Bulletin des Annonces Légales Obligatoires) dated March 20, 2013.

The documents referred to in article R.225-83 of the French Commercial Code can be consulted by the Shareholders at the head office of Technip as of today and are also available on our website at www.technip.com – Investors/2013 Annual Shareholders’ Meeting section.

Each registered shareholder may obtain these documents by mail if requested to the company at least five days prior to the date of the Meeting. Holders of bearer shares may also obtain these documents should they provide to the company a certificate of ownership via their financial intermediary.

The documents shall remain available for consultation at the head office until April 24, 2013.

°

° °

Technip is a world leader in project management, engineering and construction for the energy industry.
From the deepest Subsea oil & gas developments to the largest and most complex Offshore and Onshore infrastructures, our 36,500 people are constantly offering the best solutions and most innovative technologies to meet the world’s energy challenges.
Present in 48 countries, Technip has state-of-the-art industrial assets on all continents and operates a fleet of specialized vessels for pipeline installation and subsea construction.
Technip shares are listed on the NYSE Euronext Paris exchange and the USA over-the-counter (OTC) market as an American Depositary Receipt (ADR: TKPPY).

Technip’s website http://www.technip.com
Technip’s IR website http://investors-en.technip.com
Technip’s IR mobile website http://investors.mobi-en.technip.com

Analyst and Investor Relations
Kimberly Stewart Tel.: +33 (0)1 47 78 66 74
e-mail: kstewart@technip.com
or
Public Relations
Christophe Bélorgeot Tel.: +33 (0)1 47 78 39 …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

NYSE Euronext Announces Trading Volumes for March 2013 and Other Metrics

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

NYSE Euronext Announces Trading Volumes for March 2013 and Other Metrics

European Derivatives ADV Up Nearly 9% versus Prior Year

European, U.S. Cash Equities and U.S. Equity Options ADV Trail Prior Year

NEW YORK–(BUSINESS WIRE)– NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for March 20131. Global derivatives average daily volume (“ADV”) of 8.1 million contracts in March 2013 was in-line with March 2012, but decreased 7.8% from February 2013. European derivatives products ADV in March 2013 of 4.3 million contracts increased 8.9% compared to March 2012, but decreased 2.8% from February 2013 levels. NYSE Liffe U.S. rebounded 62.7% versus the prior month. Trading volumes in European and U.S. cash equities declined both year-over-year and month-over-month.

Highlights

  • NYSE Euronext global derivatives ADV in March 2013 of 8.1 million contracts was in line with March 2012, and decreased 7.8% from February 2013 levels.
  • NYSE Euronext European derivatives products ADV in March 2013 of 4.3 million contracts increased 8.9% compared to March 2012, but decreased 2.8% from February 2013 levels. Excluding Bclear, NYSE Liffe’s trade administration and clearing service for OTC products, European derivatives products ADV increased 21.4% compared to March 2012, but decreased 6.7% from February 2013.
  • NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of 3.8 million contracts in March 2013 decreased 8.6% compared to March 2012 levels, and decreased by 13.7% from February 2013 levels. NYSE Euronext’s U.S. options exchanges accounted for 26.9% of total U.S. consolidated equity options trading in March 2013, up from 26.0% in March 2012, but down from 28.2% in February 2013.
  • NYSE Liffe U.S. ADV of approximately 78,100 contracts decreased from 104,900 contracts in March 2012, but increased from 48,000 contracts in February 2013.
  • NYSE Euronext European cash products ADV of 1.4 million transactions in March 2013 decreased 14.4% compared to March 2012 and decreased 4.6% compared to February 2013.
  • NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE-MKT) handled ADV of 1.5 billion shares in March 2013 decreased 13.8% compared to March 2012 and …read more

    Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

IGI Laboratories, Inc. Announces Tenth ANDA Submission

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

IGI Laboratories, Inc. Announces Tenth ANDA Submission

BUENA, N.J.–(BUSINESS WIRE)– IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its second abbreviated new drug application (ANDA) in 2013 to the US FDA, which brings the company’s total number of submissions to ten.

Jason Grenfell-Gardner, President and CEO of the Company, commented, “With this submission, we remain on target to deliver on our expectation to file at least six ANDAs in 2013. The fourth quarter of 2013 will mark the three year anniversary of our first two submissions to the FDA, and based on the FDA‘s current average review time of thirty-two months, we are hopeful we could receive our first ANDA approval in 2013. Our team has filed ten ANDAs in just over two years. We believe that our successful expansion of our development pipeline is the foundation of our strategy to create long term shareholder value. We will continue to look for opportunities to accelerate the growth of our product portfolio through both our research and business development efforts.”

About IGI Laboratories, Inc.

IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “will,” “hopeful,” “believe,” “continue” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: the inability to meet current or future regulatory requirements in connection with existing or future ANDAs;; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy;; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications f

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders

NEW YORK–(BUSINESS WIRE)– Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Notice of Claims Allowance for its U.S. Patent Application No. 12/036,646. The title of the invention is Lisofylline Analogs and Methods for Use.

“This claims allowance for our U.S. patent application is another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community and our stakeholders,” said John Steel, Chairman and CEO of Islet Sciences. “We are pleased to announce this significant milestone which clearly strengthens our value proposition.”

The invention is based on the research of Timothy L. Macdonald, University of Virginia professor of chemistry and pharmacology, and Dr. Jerry L. Nadler, former chief of endocrinology and metabolism at the University of Virginia. Dr. Nadler is now Chair of Internal Medicine and Director of the Strelitz Diabetes Center at Eastern Virginia Medical School.

Dr. Jerry Nadler, MD, Founder of DiaKine Therapeutics Inc., a member of the Islet Sciences‘ Board of Directors and International Scientific Advisory Board stated, “The allowance of these claims is a wonderful positive step in helping to develop unique new drugs for unmet medical needs to treat type 1 and type 2 diabetes and related complications.”

“This exciting discovery has the potential to treat patients living with diabetes, and this action by the U.S. Patent and Trademark Office shows that it is also groundbreaking,” said Michael P. Straightiff, director of the U.Va. Licensing & Ventures Group. “I extend my congratulations to Tim, Jerry and the Islet Sciences team on their continued success in this area.”

The Notice of Claims Allowance includes composition and methods of treating a disease or disorder comprising the step of administering an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is selected from the group consisting of atherosclerosis, type 1 diabetes, type 2 diabetes, disorders associated with visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer’s disease, or any combination thereof.

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company’s infusion …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Technip, in consortium with JGC, awarded the Yamal LNG project in Russia

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Technip, in consortium with JGC, awarded the Yamal LNG project in Russia

PARIS–(BUSINESS WIRE)– Regulatory News:

Technip (Paris:TEC) (ADR:TKPPY), leader of a consortium with JGC, was awarded by JSC Yamal LNG, owned by NOVATEK (80%) and TOTAL (20%), a contract to carry out the engineering, procurement, supply, construction and commissioning of an integrated facility for natural gas liquefaction. The project will start immediately with a phase of detailed engineering, estimation and early procurement.

The facility will have an annual production capacity of 16.5 million tons and will be based on the resources of the South Tambey Gas Condensate field located on the Yamal Peninsula, Russia.

Technip’s operating center in Paris, France will execute the project.

°
° °

Technip is a world leader in project management, engineering and construction for the energy industry.

From the deepest Subsea oil & gas developments to the largest and most complex Offshore and Onshore infrastructures, our 36,500 people are constantly offering the best solutions and most innovative technologies to meet the world’s energy challenges.

Present in 48 countries, Technip has state-of-the-art industrial assets on all continents and operates a fleet of specialized vessels for pipeline installation and subsea construction.

Technip shares are listed on the NYSE Euronext Paris exchange and the USA over-the-counter (OTC) market as an American Depositary Receipt (ADR: TKPPY).

Public Relations
Christophe Bélorgeot , +33 (0) 1 47 78 39 92
Floriane Lassalle-Massip, +33 (0) 1 47 78 32 79
press@technip.com
or
Investor and Analyst Relations
Kimberly Stewart, +33 (0) 1 47 78 66 74
kstewart@technip.com
or
Chuan Wang, +33 (0) 1 47 78 36 27
chuwang@technip.com
or
Website
http://www.technip.com

KEYWORDS:   United States  Europe  North America  France  New York

INDUSTRY KEYWORDS:

The article Technip, in consortium with JGC, awarded the Yamal LNG project in Russia originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a <a target=_blank …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Islet Sciences Appoints Dr. Eitan Akirav to Scientific Advisory Board

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Islet Sciences Appoints Dr. Eitan Akirav to Scientific Advisory Board

NEW YORK–(BUSINESS WIRE)– Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in development and commercialization of patented technologies for the next generation of therapy for persons with Diabetes, today announced that Dr. Eitan Akirav has joined its Scientific Advisory Board.

“This key addition to our Scientific Advisory Board is a testament to the solid progress we have made and the leading edge therapies for diabetes that we are focused on providing,” stated Dr. Jonathan Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. “As we bolster our overall team we are proud to add Dr. Akirav to our organization and look forward to announcing additional milestones over the coming year.”

“I am pleased to announce this strategic addition to our Scientific Advisory Board as we continue to make significant progress on our growth strategy,” said John Steel, Chairman and CEO of Islet Sciences. “The expertise and deep industry relationships Dr. Akirav brings along with his significant knowledge in the field of diabetes will be quite helpful to the company moving forward. Dr. Akirav’s recent co-authorship of the American Diabetes Association study titled “Immune Therapy and β-Cell Death in Type 1 Diabetes” is clearly groundbreaking and we are thrilled that he has chosen to be a part of our esteemed Scientific Advisory Board.”

Dr. Akirav stated, “My laboratory is involved in the development of new diagnostic assays for the detection of β cell loss in diabetes. By joining Islet Sciences‘ Scientific Advisory Board I hope to deepen our collaboration and advance the company’s mission towards finding a cure for Type 1 Diabetes.”

Dr. Eitan Akirav is a Research Scientist at Winthrop-University Hospital and an Assistant Professor of Research at Stony Brook University School of Medicine in Long Island, NY. His novel work in the field of diabetes mellitus includes the development of a method for measuring dead β cell DNA in the blood. Together with Dr. Kevan Herold of Yale University, Dr. Akirav’s method provides, for the first time, a real time measurement of β cell loss during the phases of pre-diabetes, disease diagnosis, and following clinical intervention. In addition, Dr. Akirav focuses on understanding the interactions between β cells and the islet endothelium, while identifying novel factors that can improve β cell function and promote cell regeneration. Dr. Akirav collaborates with colleagues at numerous global institutions. He received a B.Sc. from Tel Aviv University (Summa Cum Laude), a M.Sc. from the University of Toronto, and a Ph.D. and postdoctoral training from …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

TriStar Wellness Solutions Signs Exclusive Global Licensing Agreement With Argentum Medical's Silver

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

TriStar Wellness Solutions Signs Exclusive Global Licensing Agreement With Argentum Medical’s Silverlon ® Technology for OTC Wound Care Market

Technology to be Combined With TriStar’s Existing Wound Care Solutions Under Development

WESTPORT, Conn.–(BUSINESS WIRE)– TriStar Wellness Solutions, Inc. (OTCQB: TWSI), a consumer health and wellness company that targets opportunities in the self-care and quality of life marketplace, has signed an exclusive, 15-year licensing agreement with Argentum Medical, LLC for its Silverlon® technology for the over-the-counter (“OTC“) wound care market.

The licensing agreement enables TriStar Wellness Solutions to develop, market and sell OTC wound care products based on Silverlon’s proprietary silver coating technology, which provides superior performance for wound treatment. The technology, with its permanently plated metallic surface, reduces the occurrence of surgical site infections. Further terms of the agreement are included in TriStar Wellness Solutions’ 8-K which was filed with the Securities and Exchange Commission on March 14, 2013.

“We expect Silverlon’s patented technology to complement the OTC wound care solutions that we are currently developing,” said John Linderman, President and CEO of TriStar Wellness Solutions. “Stopping the bleeding, protecting the wound and preventing the wound from increasing in size are all important elements of an effective wound care product, and all are characteristics of our newly licensed technology.

“TriStar Wellness Solutions’ first wound care product addresses the nuisance bleeding portion of the market, and is in an area we believe has the potential for significant growth, targeting the unmet needs of approximately 50 million Americans. We intend to capitalize on Silverlon’s technology, develop new products, and use our marketing expertise to bring these products to market, adding to our growing portfolio of brands,” concluded Mr. Linderman.

TriStar Wellness Solutions recently acquired the Beauté de Maman™ brand of women’s health products, a company that sells products into the underserved market for pregnant and new mothers. The company’s three-phased growth strategy includes incubating and commercializing its foundational product portfolio, scaling that portfolio and expanding segment extensions via targeted brand acquisitions and then leveraging its total portfolio through major corporate acquisitions and potential joint ventures. Its core strategy aligns with the growing demand for simple, effective self-care solutions for a broad range of consumer conditions and disease states.

About TriStar Wellness Solutions

TriStar Wellness Solutions, Inc. (TWSI) is a consumer health and wellness company that targets under met consumer opportunities in …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Bioject Enters into Three Distribution Agreements

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Bioject Enters into Three Distribution Agreements

Two in the Pacific Rim and One in the Middle East

TIGARD, Ore.–(BUSINESS WIRE)– Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today announced that it has entered into three international distribution agreements, two in the Pacific Rim region and one in the Middle East. The agreements call for the sale of the Biojector®2000 gas-powered device, the Bioject® ZetaJet™ spring-powered device and accessories through qualified medical device groups located in Australia, the Republic of the Philippines, and North Africa. The agreements provide for distribution in multiple territories throughout the regions.

“We are pleased to have entered into these agreements, as it expands the use of our needle-free devices throughout the world,” said Mr. Mark Logomasini, Bioject’s President and CEO. “In partnership with our distributors, we are looking forward to developing relationships with new users of Bioject’s needle-free technology.”

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

Readers and potential investors are cautioned that an investment in the Company’s securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that these distribution agreements will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the business.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company onwww.otcmarkets.com.

For more information about Bioject, visitwww.bioject.com.

Bioject Medical Technologies Inc.
Mark Logomasini, 503-692-8001 ext. 4121
President and CEO
or
Christine Farrell, 503-692-8001 ext. 4132
Vice President of Finance

KEYWORDS:   Australia  United States  Asia Pacific  North America  Australia/Oceania  Philippines  Oregon  …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Saving Fannie Mae and Freddie Mac, The Pen Mightier Than The Sword

Leave a comment

By 24/7 Wall St.

House for Sale

Filed under: , , , , ,

Are Fannie Mae and Freddie Mac really still safe from the bankruptcy chamber? 24/7 Wall St. is looking for a reality check here and we find it surprising that the giant moves here have hardly taken on the attention deserved for such a dire situation. Fannie Mae (FNM) and Federal Home Loan Mortgage Corporation (FMCC) are both surging to new 52-week highs and it may be an instance where this is simply the pen being mightier than the sword.

The Wall Street Journal previously brought attention to an SEC filing from last Thursday showing that Fannie Mae would delay its annual report because it needed more time to evaluate whether or not it could recapture some of its valuation allowance for deferred tax assets as of the end of 2012. It is no small sum either: $64.1 billion. That being said, traders, investors and speculators are all going to be paying close attention here.

As a reminder, both Fannie Mae and Freddie Mac remain under government conservatorship. They are mathematically bankrupt, but that is a different story. It is also hard to call companies bankrupt when their shares are up so much.

Fannie Mae shares are up a whopping 43% at $0.7468 on more than 66 million shares. Federal Home Loan Mortgage Corporation (FMCC) shares are up 38% at $0.715 on about 30 million shares.

It is hard to imagine this being possible, but technically these companies might be eligible to get listed on proper non-OTC exchanges if there is another day of gains like this. Of course those share prices would have to remain above the $1.00 for 30 to 45 days, but that is another matter.

It seems odd to see that MBIA Inc. (NYSE: MBI) is down almost 4% at $11.35 after runs like this.

Filed under: 24/7 Wall St. Wire, Accounting, Active Trader, Annual Report, Banking & Finance, Cult Stock, Earnings, Economy, Housing Tagged: FMCC, FNMA, MBI

Read | Permalink | Email this | Linking Blogs | Comments

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Tristar Wellness Solutions Engages Dian Griesel Inc.

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Tristar Wellness Solutions Engages Dian Griesel Inc.

Initiates Campaign of Investor and Media Outreach to Strengthen Company Awareness

WESTPORT, Conn.–(BUSINESS WIRE)– TriStar Wellness Solutions, Inc. (OTCQB: TWSI), a consumer health and wellness company that targets opportunities in the self-care and quality of life marketplace, has hired Dian Griesel Inc. (DGI) to serve as its investor relations and public relations agency. DGI’s investor and public relations teams will work towards the objective of increasing investor and public awareness of TriStar Wellness Solutions’ unique business model, unmet needs in consumer health and brands in the company’s portfolio.

“TriStar Wellness Solutions is focused on incubating science-based product innovations and addressing under-met consumer needs in niche, but highly engaged, consumer health and wellness spaces,” said John Linderman, President and CEO of TriStar Wellness Solutions. “Our core strategy aligns with the growing demand for simple, effective self-care solutions for a broad range of consumer conditions and disease states. We believe that we have a compelling investment thesis for investors and an exciting story to share with the media, and we look forward to leveraging DGI’s experience, relationships and expertise.”

DGI is a full-service corporate communications firm providing the equivalent of “large-cap” investor relations and public relations services to smaller emerging growth companies. Always budget-conscious, its carefully planned programs blend the best of traditional strategies with the opportunities of new media.

About TriStar Wellness Solutions

TriStar Wellness Solutions, Inc. (TWSI) is a consumer health and wellness company that targets under met consumer opportunities in the OTC marketplace. Our core strategy plans to meet the growing demand for personalized, consumer self-care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar Wellness Solutions is owner of the Beaute de MamanTM brand of women’s health products. Additional information is available at www.tstarwellness.com and http://www.beautedemaman.com

Forward-Looking Statement

This press release for TriStar Wellness Solutions, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like “anticipates,” “believes,” “expects,” “future,” “intends,” “plans,” and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Pernix Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Pernix Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results


Completed Acquisition of Cypress Pharmaceuticals and Hawthorn Pharmaceuticals


Completed the Acquisition of Somaxon Pharmaceuticals in March 2013


Announced Plans to Launch Dr. Cocoa, an OTC Chocolate Flavored Cough & Cold Product Line

THE WOODLANDS, Texas–(BUSINESS WIRE)– Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NAS: PTX) , a specialty pharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2012.

Financial Results

For the fourth quarter of 2012, net revenues were $18.2 million, compared to $21.4 million for the fourth quarter of 2011. Total net product revenues consisted of 53% revenue contribution from branded products and 47% revenue contribution from generic products in the fourth quarter of 2012.

The net loss for the fourth quarter of 2012 was approximately $(1.4) million, or $(0.05) per basic and diluted share, compared to net income of $3.9 million, or $0.15 per basic and diluted share, for the fourth quarter of 2011.

“This past year was a time for investing and building in Pernix’s continued success,” said Cooper Collins, President and Chief Executive Officer of Pernix. “Looking forward in 2013, we are focused on several key objectives that are expected to drive the Company’s future growth, which include the following: integrating Cypress and Hawthorn, re-launching Silenor by our newly-combined Pernix and Hawthorn sales forces, initiating our Phase III clinical trials for our pediatric product, launching Dr. Cocoa, an OTC chocolate flavored cough and cold product for the 2013-2014 cough and cold season, beginning the development of Silenor as an OTC product, and working toward the IND filings of two products in Hawthorn’s pipeline. We are also capitalizing on the synergies of our acquisitions, and improving efficiencies across all of our operations.”

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Cohen Milstein Sellers &amp; Toll PLLC Announces the Investigation of Poseidon Concepts Corp.

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Poseidon Concepts Corp.

WASHINGTON–(BUSINESS WIRE)– Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Poseidon Concepts Corp. (“Poseidon” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Several class action lawsuits were filed in the U.S. District Court for the Southern District of New York by other law firms on behalf of purchasers of the publically traded common stock of Poseidon between May 9, 2012 and February 14, 2013, inclusive (the “Class Period”).

The complaints allege that Poseidon and certain of its officers and directors (“Defendants”) issued false and misleading statements and omitted material information concerning the Company’s business prospects, financial performance, and true financial condition.

On December 27, 2012, Poseidon suspended its dividend payments and formed a Special Committee to “review and address various issues arising from the recent write-off of certain accounts receivable and the evolving business plan of the Company.”

On February 14, 2013, Poseidon announced the results of the Special Committee investigation, reporting that it would have to restate its results for the first three quarters of 2012. The Committee found that approximately $95 million to $106 million of the $148.1 million in revenue the Company had reported for the first three quarters of 2012 “should not have been recorded as revenue,” and additionally found that approximately $94 million to $102 million of the Company’s reported accounts receivable at September 30, 2012 “should not have been recorded” as such. The price of Poseidon shares fell from $0.89 to $0.28 on February 14.

Cohen Milstein encourages all investors who purchased Poseidon common stock in the United States on the OTC market (OTC: POOSF) between May 9, 2012 and February 14, 2013, or former employees with information concerning this matter, to contact the firm.

If you purchased Poseidon shares in the United States on the OTC market and would like to discuss your right to recover for your economic loss, you may, without any cost or obligation, call Cohen Milstein‘s Managing Partner, Steven J. Toll at (888) 240-0775 or (202) 408-4600, or email him at stoll@cohenmilstein.com. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2013 to request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. To be appointed lead plaintiff, the Court must decide that …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Northern Trust Enhances Operational Support for Central Counterparty Clearing of OTC Derivatives

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Northern Trust Enhances Operational Support for Central Counterparty Clearing of OTC Derivatives

CHICAGO–(BUSINESS WIRE)– To help clients comply with new regulations intended to manage risk in the financial derivatives markets, Northern Trust has enhanced its systems to provide operational support for central clearing of certain over-the-counter (OTC) derivatives.

New capabilities allow Northern Trust to electronically capture trade information on swaps, a widely used type of OTC derivative, and connect with external parties to route trades to electronic matching platforms, clearing firms and exchanges. The enhancements to Northern Trust‘s custody and middle-office platform will support compliance with the Dodd-Frank Act in the United States and the European Markets Infrastructure Regulation (EMIR), which require investors to clear OTC derivatives through centralized exchanges, rather than on a bilateral basis.

“As the infrastructure for derivatives transactions moves toward central counterparty (CCP) clearing, we have developed processing efficiencies that allow us to electronically capture and confirm CCP trades, interface with the exchanges and clearing firms, and offer margin management,” said Judson Baker, Product Manager for Derivatives and Collateral Management at Northern Trust. “Our ability to provide these services saves our clients from having to make costly investments in systems and operational support needed to meet regulatory requirements.”

Available on a global basis to investment managers, institutional investors and other asset servicing clients, the new capabilities are integrated with Northern Trust‘s Investment Operations Outsourcing, global custody and collateral management systems to support all aspects of post-trade processing.

“The regulatory environment continues to evolve, bringing greater demand for derivatives services,” said Peter Cherecwich, Head of Global Fund Services at Northern Trust. “We are committed to investing in automation and increased product coverage to fully support derivatives processing, including margin management, in support of our back and middle office outsourcing clients.”

Northern Trust offers an active collateral management service for clients that trade futures and listed options, OTC and cleared swaps. Northern Trust provides this service for an array of derivative participants including asset managers, corporations, pension funds and family offices located around the globe. In addition, Northern Trust will continue to invest in operational capabilities in support of margin management to help clients optimize their pledged assets.

About Northern Trust

Northern Trust Corporation (NAS: NTRS) is a leading provider of investment management, asset and fund administration, banking solutions and fiduciary services for corporations, institutions and affluent individuals worldwide. …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Pernix Therapeutics to Present at the 25th Annual ROTH Growth Conference

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Pernix Therapeutics to Present at the 25th Annual ROTH Growth Conference

THE WOODLANDS, Texas–(BUSINESS WIRE)– Pernix Therapeutics Holdings, Inc. (NAS: PTX) , a specialty pharmaceutical company, today announced that Cooper Collins, President and Chief Executive Officer, will present at the 25th Annual ROTH Growth Stock Conference on Tuesday, March 19, 2013 at 9:30 a.m. PDT. The conference will be held at The Ritz Carlton in Dana Point, CA.

The presentation will be broadcast live over the Internet and can be accessed on the Company’s website, www.pernixtx.com, under “Webcasts and Presentation” on the investor relations section. The audio-recording of the presentation will be archived on the Company’s website for approximately 30 days following the conclusion of the presentation.


About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded products, including the recently acquired Hawthorn Pharmaceuticals‘ product line. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. A product candidate utilizing cough-related intellectual property is in development for the U.S. OTC market. Founded in 1996, the Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, 800-793-2145 ext. 3002
Director, Investor Relations
jschepers@pernixtx.com

KEYWORDS:   United States  North America  California  Texas

INDUSTRY KEYWORDS:

The article Pernix Therapeutics to Present at the 25th Annual …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

NYSE Euronext Announces Trading Volumes for February 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

NYSE Euronext Announces Trading Volumes for February 2013

Global Derivatives ADV Up 25% Y-o-Y Driven by Strong Fixed Income Trading, Up 71%

European Cash Equity ADV Up 13% M-o-M; U.S. Cash Equity ADV Up 1% M-o-M

U.S. Equity Options ADV Up 6% Y-o-Y

NEW YORK–(BUSINESS WIRE)– NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for February 20131. Global derivatives average daily volume (“ADV“) of 8.8 million contracts in February 2013 increased 24.7% compared to February 2012, but decreased 7.6% month-over-month. This increase was primarily driven by stronger European derivatives volume, specifically fixed income derivatives ADV which increased 71% year-over-year. U.S. equity options ADV increased 5.7% compared to February 2012, but decreased 9.8% from January 2013 levels. Trading volumes in European cash equities were down 9.8% year-over-year, but rebounded up 12.8% month-over-month.

Highlights

  • NYSE Euronext global derivatives ADV in February 2013 of 8.8 million contracts increased 24.7% compared to February 2012, but decreased 7.6% from January 2013 levels.
  • NYSE Euronext European derivatives products ADV in February 2013 of 4.4 million contracts increased 54.4% compared to February 2012, but decreased 10.0% from January 2013 levels. Excluding Bclear, NYSE Liffe’s trade administration and clearing service for OTC products, European derivatives products ADV increased 45.7% compared to February 2012, but decreased by 5.2% from January 2013.
  • NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex) ADV of 4.3 million contracts in February 2013 increased 5.7% compared to February 2012 levels but decreased by 5.2% from January 2013 levels. NYSE Euronext’s U.S. options exchanges accounted for 28.2% of total U.S. consolidated equity options trading in February 2013.
  • NYSE Euronext European cash products ADV of 1.5 million transactions in February 2013 decreased 9.8% compared to February 2012, but increased 12.8% compared to January 2013.
  • NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.6 billion shares in February 2013 decreased 11.9% compared to February 2012 but …read more
    Source: FULL ARTICLE at DailyFinance